The study - conducted in nonhuman primates with brain structures and functions similar to those of humans - found that the antidepressant sertraline, a selective serotonin reuptake inhibitor (SSRI) marketed as Zoloft, significantly increased the volume of one brain region in depressed subjects but decreased the volume of two brain areas in non-depressed subjects. "These observations are important for human health because Zoloft is widely prescribed for a number of disorders other than depression," said Carol A. D., professor of pathology-comparative medicine at Wake Forest Baptist and lead author of the study, published in the current online issue of the journal Neuropharmacology. In the study, 41 middle-aged female monkeys were fed a diet formulated to replicate that consumed by many Americans for 18 months, during which time depressive behavior in the animals was recorded. Female monkeys were chosen for this study because depression is nearly twice as common in women as men and the use of antidepressants is most common in women ages 40 to 59. After the 18-month pre-study phase, the monkeys were divided into two groups balanced for body weight, body mass index and depressive behavior. For the next 18 months, 21 monkeys received sertraline in daily doses comparable to those taken by humans while a group of 20 received a placebo. This treatment regimen is analogous to a human taking an antidepressant for approximately five years. Jane Doe, a 48-year-old accountant with a 30-year history of Obsessive-Compulsive Disorder (OCD) mainly related to checking behaviour, presents with a worsening of mental state. She has been on Sertraline 300 mg OD for the last 20 years and been well controlled. What led to the deterioration and how was the patient treated? The case highlights the importance of avoiding a reductionistic approach and using deconstruction of the mental health disorder in formulation and management. The main circuits involved in OCD are the Cortico-thalamic-striatal- cortical loop (CTSC). Overactivation of this ‘worry loop’ is responsible for the development of obsessions. Selective Serotonin Reuptake Inhibitors (SSRI’s) at higher doses are effective in addressing the malfunctioning in this critical loop to treat the OCD.
Selective serotonin reuptake inhibitors (SSRIs) are a first-line treatment for depression. Recent reports in the literature describe differences in antidepressant effects among SSRIs. Although each SSRI apparently has different pharmacological actions aside from serotonin reuptake inhibition, the relations between antidepressant effects and unique pharmacological properties in respective SSRIs remain unclear. This study was designed to compare abilities of three systemically administered SSRIs… Efficacy has been demonstrated in depression, dysthymia, OCD, social anxiety, panic disorder, PTSD, premature ejaculation, and premenstrual dysphoric disorder. It's also sometimes used for eating disorders. The core effect of the substance is that it alters mood. This could mean less anxiety, less depression, a more positive outlook, improved cooperation with others, and greater assertiveness. SSRIs may initially worsen symptoms like depression and anxiety in some people. This changes over a period of weeks, with the efficacy building over time. Some benefits in depression may be noticed in the first 1-2 weeks, but the greatest clinical efficacy arrives in the first couple months.
Degenerates dopaminergic neurons 3. Sertraline and venlafaxine are well known for their use in the treatment and management of depression and these drugs. Sep 11, 2016. She has been on Sertraline 300 mg OD for the last 20 years and been. 5HT2C activation of GABA neurones which in turn reduce dopamine.